What is the place of thrombolysis in acute stroke? A review of the literature and a current perspective

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 3, 2008, Pages 253-258

  Jenkins, Peter O ^a,e   Turner, Martin R ^b,c   Jenkins, Paul F ^d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

Cerebral haemorrhage; Cerebral infarction; Cost effectiveness; Stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 46949106606     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-3-253     Document Type: Review

References (52)

1. Del Zoppo GJ, Poeck K, Pessin MS et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
2. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 of acute myocardial infarction. Lancet 1988;ii:349-60.
3. Papadopoulos SM, Chandler WF, Salamat MS et al. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg 1987;67:394-8.
4. Pereira AC, Martin PJ, Warburton EA. Thrombolysis in acute ischaemic stroke. Postgrad Med J 2001;77:166-71.
5. Ohtomo E, Araki G, Itoh E et al. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Multi-centre double-blind study in comparison with placebo (Translated from Japanese). Clin Eval 1985; 15:711-31.
6. Atarashi J, Ohtomo E, Araki G et al. Clinical utility of urokinase in the treatment of acute stage cerebral thrombosis: Multi-centre double blind study in comparison with placebo (Translated from Japanese). Clin Eval 1985;13:659-709.
7. Abe T, Kazama M, Naito I et al. Clinical evaluation for efficacy of tissue cultured urokinase on cerebral thrombosis by means of multicentre double-blind study (Translated from Japanese). Blood Vessel 1981;12:321-41.
8. Yamaguchi T, Hayakawa T, Kiuchi H, Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993;3:269-72.
9. Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-82.
10. Haley EC, Brott TG, Sheppard GL et al. Pilot randomized trial of tissue plasminogen activator in acute ischaemic stroke. Stroke 1993; 24:1000-4.
11. Morris AD, Ritchie C, Grosset DG, Adams FG, Lees KR. A pilot study of streptokinase for acute cerebral infarction. Q J Med 1995;88:727-31.
12. Donnan GA, Davis SM, Chambers BR et al, and for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischaemic stroke with relationship to time of administration. JAMA 1996;276:966.
13. Multicenter Acute Stroke Trial Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
14. Multi-centre Acute Stroke Trial Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
15. Hacke W, Kaste M, Fieschi C et al, and for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017-25.
16. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
17. Hacke W, Kaste M, Fieschi CW et al. Randomised double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352: 1245-51.
18. Clark WM, Wissman S, Albers GW et al, and for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (alteplase) for ischaemic stroke 3 to 5 hours after symptom onset. JAMA 1999;282:2019-26.
19. Chen QT, He M. Intravenous thrombolysis with urokinase for acute cerebral infarction. Chin J Neurol 2002;35:210-8.
20. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Revi 2003;3CD000213.
21. Donnan GA, Davis SM, Chambers BR et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995;345:578-9.
22. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
23. Kwiatkowski TG, Libman RB, Frankel M et al. Effects of tissue plasminogen activator for acute ischaemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340: 1781.
24. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS Trial: results for patients treated within three hours of stroke onset. Stroke 2002;33:493.
25. Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischaemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66.
26. Furlan AJ, Eyding D, Albers GW et al. Dose Escalation of Desmoteplase for Acute Ischaemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227.
27. Liberatore GT, Samson A, Bladin C et al. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537.
28. Reddrop C, Moldrich RX, Beart PM et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005;36:1241.
29. del Zoppo GJ, Higashida RT, Furlan AJ et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4.
30. Furlan AJ, Higashida RT, Wechsler L et al. Intra-arterial pro-urokinase for acute ischaemic stroke. The PROACT II study: a randomised controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003.
31. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the 'brain attack' campaign. BMJ 2002;324:723.
32. Mann J. Truths about the NINDS study: setting the record straight. West J Med 2002;176:192.
33. Trotter G. Why were the benefits of tPA exaggerated? West J Med 2002; 176:194.
34. Wardlaw JM, Lindley RI, Lewis S. Thrombolysis for acute ischaemic stroke: still a treatment for the few by the few. West J Med 2002;176:198.
35. Marler JR, Tilley BC, Lu M et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55:1649-55.
36. Ingall TJ, O'Fallon WM, Asplund K et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischaemic stroke treatment trial. Stroke 2004;35:2418-24.
37. Kwiatkowski T, Libman R, Tilley BC et al. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med 2005;45:377.
38. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischaemic stroke: the Cleveland area experience. JAMA 2000;283:1151.
39. Wahlgren N, Ahmed N, Davalos A et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82.
40. Libman RB, Wirkowski E, Alvir J, Rao TH. Conditions that mimic stroke in the emergency department: Implications for acute stroke trials. Arch Neurol 1995;52:1119-22.
41. Liebeskind DS, Kidwell CS, Sayre JW, Saver JL. Evidence of publication bias in reporting acute stroke clinical trials. Neurology 2006;67:973-9.
42. Schenkel J, Weimar C, Knoll T et al. R1 - systemic thrombolysis in German stroke units - the experience from the German Stroke data bank. J Neurol 2003;250:320-4.
43. Szoeke CE, Parsons MW, Butcher KS et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003;178:324-8.
44. Katzan IL, Hammer MD, Hixson ED et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-50.
45. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64:654-9.
46. Jorgensen HS, Nakayama H, Kammersgaard LP, Raaschou HO, Olsen TS. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model. BMJ 1999; 319:288-9.
47. National Audit Office/Department of Health. Reducing brain damage: faster access to better stroke care. London: Stationery Office, 2005.
48. Fagan S, Morgenstern L, Pettita A et al. Cost-effectiveness of tissue plasminogen activator for acute ischaemic stroke. Neurology 1998;50: 883-90.
49. Sandercock P, Berge E, Dennis M et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischaemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-7.
50. Donaldson C, Currie C, Mitton C. Cost-effectiveness analysis in health care: contraindications. BMJ 2002;235:891-4.
51. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The role of acute MRI for patient selection. Stroke 1999;30: 2230-7.
52. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-63.